Aspergillus Lateral Flow Assay with Digital Reader for the Diagnosis of COVID-19 Associated Pulmonary Aspergillosis (CAPA): A multicenter study
| Autor: | Jean-Pierre Gangneux, P. Lewis White, Juergen Prattes, Matthias Egger, Jessica S Price, Marina Machado, Maricela Valerio, Brice Autier, Martin Hoenigl |
|---|---|
| Přispěvatelé: | Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), École des Hautes Études en Santé Publique [EHESP] (EHESP), Medical University Graz, University Hospital of Wales (UHW), Hospital General Universitario 'Gregorio Marañón' [Madrid], Karl-Franzens-Universität Graz, CHU Pontchaillou [Rennes], University of California [San Diego] (UC San Diego), University of California (UC), Provided some of the LFA test kits, IMMY Diagnostics, Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), University Hospital of Wales [Cardiff, UK], Karl-Franzens-Universität [Graz, Autriche], University of California, University of Graz, Hanson, Kimberly E, Jonchère, Laurent |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
[SDV]Life Sciences [q-bio]
nondirected bronchial lavage Gastroenterology Medical and Health Sciences law.invention Mannans chemistry.chemical_compound 0302 clinical medicine law Cutoff bronchoalveolar lavage tracheal aspirate Lung Invasive Pulmonary Aspergillosis 0303 health sciences medicine.diagnostic_test biology Area under the curve Biological Sciences Intensive care unit 3. Good health Aspergillus galactomannan lateral flow assay (LFA) [SDV] Life Sciences [q-bio] Infectious Diseases Aspergillus Bronchoalveolar Lavage Fluid Microbiology (medical) medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Microbiology Sensitivity and Specificity 03 medical and health sciences Galactomannan Rare Diseases Clinical Research Internal medicine medicine Aspergillus galactomannan lateral flow assay Humans Retrospective Studies Receiver operating characteristic Agricultural and Veterinary Sciences 030306 microbiology business.industry SARS-CoV-2 COVID-19 biology.organism_classification Bronchoalveolar lavage 030228 respiratory system chemistry galactomannan Pulmonary Aspergillosis business serum |
| Zdroj: | Journal of Clinical Microbiology Journal of Clinical Microbiology, 2022, 60 (1), pp.JCM0168921. ⟨10.1128/JCM.01689-21⟩ Journal of Clinical Microbiology, American Society for Microbiology, 2021, pp.JCM0168921. ⟨10.1128/JCM.01689-21⟩ Journal of clinical microbiology, vol 60, iss 1 |
| ISSN: | 0095-1137 |
| DOI: | 10.1128/JCM.01689-21⟩ |
| Popis: | International audience; This multicenter study evaluated the IMMY Aspergillus Galactomannan Lateral Flow Assay (LFA) with automated reader for diagnosis of pulmonary aspergillosis in patients with COVID-19 associated acute respiratory failure (ARF) requiring intensive care unit (ICU) admission between 03/2020 and 04/2021. A total of 196 respiratory samples and 148 serum samples (n=344) from 238 patients were retrospectively included, with a maximum of one of each sample type per patient. Cases were retrospectively classified for COVID-19 associated pulmonary aspergillosis (CAPA) status following the 2020 consensus criteria, with the exclusion of LFA results as a mycological criterion. At the 1.0 cutoff, sensitivity of LFA for CAPA (proven/probable/possible) was 52%, 80% and 81%, and specificity was 98%, 88% and 67%, for bronchoalveolar lavage fluid (BALF), non-directed bronchoalveolar lavage (NBL), and tracheal aspiration (TA), respectively. At the 0.5 manufacturer’s cutoff, sensitivity was 72%, 90% and 100%, and specificity was 79%, 83% and 44%, for BALF, NBL and TA, respectively. When combining all respiratory samples, the receiver operating characteristic (ROC) area under the curve (AUC) was 0.823, versus 0.754, 0.890 and 0.814 for BALF, NBL and TA, respectively. Sensitivity and specificity of serum LFA were 20% and 93%, respectively, at the 0.5 ODI cutoff. Overall, the Aspergillus Galactomannan LFA showed good performances for CAPA diagnosis, when used from respiratory samples at the 1.0 cutoff, while sensitivity from serum was limited, linked to weak invasiveness during CAPA. As some false positive results can occur, isolated results slightly above the recommended cutoff should lead to further mycological investigations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|